HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

New: Introducing the Finviz Futures Map

Learn More

CURX

Curanex Pharmaceuticals Inc

Last Close
Aug 27 • 04:00PM ET
4.66
Dollar change
+0.64
Percentage change
15.92 		%
Healthcare • Biotechnology • USA • NASD
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-
Enterprise Value- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Income- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Sales- P/B- EPS next Y- ROA- Short Interest- Perf YTD15.92%
Book/sh- P/C- EPS next 5Y- ROE- 52W High4.18 11.48% Perf Year-
Cash/sh- P/FCF- EPS past 3/5Y- - ROIC- 52W Low3.61 29.09% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility- - Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)0.72 Perf 10Y-
Dividend Ex-Date- Quick Ratio- Sales Y/Y TTM- Profit Margin- RSI (14)- Recom-
Dividend Gr. 3/5Y- - Current Ratio- EPS Q/Q- SMA207.37% Beta- Target Price-
Payout- Debt/Eq- Sales Q/Q- SMA507.37% Rel Volume0.15 Prev Close4.02
Employees- LT Debt/Eq- Earnings- SMA2007.37% Avg Volume5.25M Price4.66
IPOAug 26, 2025 Option/ShortNo / No EPS/Sales Surpr.- - Trades Volume793,626 Change15.92%
Today 05:00PM
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
(GlobeNewswire) +15.92%
Aug-26-25 07:30AM
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
(GlobeNewswire)
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patientsa lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.